Valuation : Laboratorios Richmond S.A.C.I.F.

Market Cap 13TCr 8.49Cr 7.31Cr 6.88Cr 6.28Cr 12Cr 801.83Cr 12Cr 81Cr 32Cr 411.39Cr 32Cr 31Cr 1.33TCr P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 36TCr 24Cr 20Cr 19Cr 18Cr 33Cr 2.25TCr 33Cr 227.91Cr 88Cr 1.15TCr 89Cr 88Cr 3.72TCr EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
06/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
07/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/24/06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/24/13 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/24/07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/24/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+1.60%
1 week+0.96%
Current month-1.55%
1 month+3.26%
3 months-2.76%
6 months+1.60%
Current year-19.75%
1 week 1,530
Extreme 1530
1,615
1 month 1,495
Extreme 1495
1,615
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%+0.96%+38.43%+176.13% 8.49Cr
-0.88%-2.15%+58.05%+105.91% 1,02400Cr
-1.15%+2.68%+54.25%+71.29% 66TCr
-1.44%+0.38%+20.65%+75.54% 45TCr
+0.14%-0.47%+30.20%+40.61% 35TCr
-1.33%+4.72%+24.62%+47.60% 30TCr
-1.15%+0.30%-0.69%+11.83% 25TCr
-1.55%+1.11%+54.15%+72.13% 24TCr
-0.88%+1.15%-14.60%-54.84% 21TCr
-0.15%+3.65%+31.24%+100.90% 19TCr
Average -0.68%+0.83%+29.63%+64.71% 36.78TCr
Weighted average by Cap. -0.96%+0.55%+37.63%+67.00%

Financials

2024 2025
Net sales 9.18TCr 6.09Cr 5.24Cr 4.93Cr 4.5Cr 8.43Cr 575.07Cr 8.45Cr 58Cr 23Cr 295.05Cr 23Cr 22Cr 950.51Cr 13TCr 8.41Cr 7.24Cr 6.81Cr 6.22Cr 12Cr 793.9Cr 12Cr 80Cr 31Cr 407.33Cr 32Cr 31Cr 1.31TCr
Net income 2.38TCr 1.58Cr 1.36Cr 1.28Cr 1.17Cr 2.19Cr 149.38Cr 2.19Cr 15Cr 5.87Cr 77Cr 5.94Cr 5.81Cr 246.91Cr 308.78Cr 20.49L 17.63L 16.59L 15.15L 28.35L 19Cr 28.42L 1.96Cr 76.06L 9.93Cr 76.94L 75.26L 32Cr
Net Debt 13TCr 8.87Cr 7.63Cr 7.18Cr 6.56Cr 12Cr 837.26Cr 12Cr 85Cr 33Cr 429.57Cr 33Cr 33Cr 1.38TCr 23TCr 15Cr 13Cr 12Cr 11Cr 21Cr 1.45TCr 21Cr 146.66Cr 57Cr 742.6Cr 58Cr 56Cr 2.39TCr
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
04/26/04 ARS 1,585.00 +1.60% 3,631
03/26/03 ARS 1,560.00 -1.58% 1,635
02/26/02 ARS 1,585.00 +2.26% 1,189
01/26/01 ARS 1,550.00 -3.73% 1,659
31/26/31 ARS 1,610.00 +2.55% 5,467
  1. Stock Market
  2. Stocks
  3. RICH Stock